Biotie
Sumitomo Pharma’s stem cell therapy for Parkinson’s given limited approval in Japan
The company has been given manufacturing and marketing authorisation for the therapy
Annovis partners with NeuroRPM on new AI platform to track Parkinson’s symptoms
The platform will passively collect data to understand treatment responses in everyday life
Minds + Assembly Launches Assembled Intelligence and Adds Stratevi to Expand Market Access and HEOR Solutions
New York, NY — 10.23.2025 — Minds + Assembly, a leading healthcare marketing firm, today announced the launch of Assembled Intelligence, an integrated communications and commercialization platform designed to unite...
Mission Therapeutics advances Parkinson’s disease candidate
The company also received a grant from the Michael J. Fox Foundation and Parkinson’s UK
PhotoPharmics’ new advisory board to guide launch of FDA Breakthrough device for Parkinson’s
The US-based company develops light-based therapies for neurodegenerative conditions
GSK and Vesalius partner on new Parkinson’s treatments in deal worth $650m
The alliance is aimed at developing treatments for Parkinson's and another neurodegeneration indication
Researchers develop AI blood test to predict Parkinson’s seven years before symptom onset
The neurodegenerative condition currently affects nearly ten million people worldwide
Cerevel Therapeutics shares positive phase 3 results for tavapadon in Parkinson’s disease
The progressive neurodegenerative disease affects seven million people worldwide
Co-funded trial shows promise for Sanofi’s diabetes drug in early Parkinson’s disease
According to WHO, the neurodegenerative disease affected more than 8.5 million people worldwide in 2019
Two UK clinical trials launched to identify blood tests for dementia diagnosis
The neurodegenerative condition affects more than 944,000 people in the UK
NeuroDerm shares positive phase 3 results for investigational Parkinson’s disease therapy
The progressive neurodegenerative disease affects around ten million people worldwide
AbbVie’s Produodopa rolled out by NHS England for advanced Parkinson’s patients
The roll out follows NICE’s recommendation of the treatment in October 2023